secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001104659-24-096021
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix appoints Donald Notman as COO, retains CFO role
------------------------------------------------------------------

- Donald Notman, age 65, appointed COO on August 29, 2024; continues as CFO and principal financial and accounting officer.
- Notman has served as CFO since September 2017; prior roles include CFO of Thrasos Therapeutics and Managing Director at Leerink Swann.
- No arrangements or family relationships with other directors/officers; no related party transactions under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924096021/0001104659-24-096021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924096021/tm2423106d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-096021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer